Drug intelligence / Profile preview

ABV-1703

Development stage: Unknown
Lead developer: ABVC BioPharma
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

ABV-1703 is a botanical drug candidate developed for the treatment of pancreatic cancer. The drug's active pharmaceutical ingredient is BLEX 404, a β-glucan extracted from the Maitake mushroom (*Grifola frondosa*). Originally developed by ABVC BioPharma in collaboration with its affiliates BioLite and Rgene Corporation, the asset was licensed to OncoX BioPharma for further clinical development and commercialization. ABV-1703 has received Investigational New Drug (IND) approval from the FDA and is being evaluated for its immunomodulatory effects, leveraging the natural properties of mushroom-derived polysaccharides to stimulate an anti-tumor immune response.

Other names: BLEX 404BLEX404BLEX-404

Beyond the preview

Go deeper on ABV-1703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABV-1703.

Explore the full profile